Journal
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
Volume 27, Issue 4, Pages 527-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.coms.2015.06.006
Keywords
Osteonecrosis of the jaw (ONJ); Bisphosphonates; Antiresorptives; Risk; Prevention
Categories
Ask authors/readers for more resources
For patients at risk of osteonecrosis of the jaw (ONJ), information can be provided by the pharmaceutical manufacturer, pharmacist, prescribing physician, dentist, and oral and maxillofacial surgeon. Prevention strategies to reduce the incidence of osteonecrosis should be applied as soon as it is determined that a patient will be placed on antiresorptive medication. Proper screening involves a comprehensive oral examination with radiographs followed by oral hygiene instruction and necessary dental treatment; surgical techniques and adjunctive therapies that favor optimum healing of bone and soft tissue decrease the risk of ONJ. No dental procedures are absolutely contraindicated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available